Affordable Access

deepdyve-link
Publisher Website

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

Authors
  • Lalonde, Emilie1
  • Alkallas, Rached2
  • Chua, Melvin Lee Kiang3
  • Fraser, Michael4
  • Haider, Syed2
  • Meng, Alice4
  • Zheng, Junyan4
  • Yao, Cindy Q2
  • Picard, Valerie5
  • Orain, Michele5
  • Hovington, Helène5
  • Murgic, Jure3
  • Berlin, Alejandro3
  • Lacombe, Louis5
  • Bergeron, Alain5
  • Fradet, Yves5
  • Têtu, Bernard5
  • Lindberg, Johan6
  • Egevad, Lars7
  • Grönberg, Henrik6
  • And 9 more
  • 1 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. , (Canada)
  • 2 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada. , (Canada)
  • 3 Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, ON, Canada. , (Canada)
  • 4 Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. , (Canada)
  • 5 Centre de recherche du CHU de Québec-Université Laval, Québec City, QC, Canada. , (Canada)
  • 6 Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. , (Sweden)
  • 7 Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden. , (Sweden)
  • 8 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • 9 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK; Department of Urology, Addenbrooke's Hospital, Cambridge, UK; Academic Urology Group, University of Cambridge, Cambridge, UK.
  • 10 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK; Department of Urology, Addenbrooke's Hospital, Cambridge, UK.
  • 11 Department of Biostatistics, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. , (Canada)
  • 12 Department of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, ON, Canada. , (Canada)
  • 13 Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, ON, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. Electronic address: [email protected] , (Canada)
  • 14 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: [email protected] , (Canada)
Type
Published Article
Journal
European urology
Publication Date
Jul 01, 2017
Volume
72
Issue
1
Pages
22–31
Identifiers
DOI: 10.1016/j.eururo.2016.10.013
PMID: 27815082
Source
Medline
Keywords
License
Unknown

Abstract

It is challenging to determine whether tumors confined to the prostate are aggressive, leading to significant undertreatment and overtreatment. We validated a test based on prostate tumor DNA that improves estimations of relapse risk, and that can help guide treatment planning.

Report this publication

Statistics

Seen <100 times